Answers are grounded in this paper and cite their sources.
Retrospective cohort analysis suggests statins may improve median survival in TKI-exposed patients, indicating a potential cardioprotective role.
Background Tyrosine kinase inhibitors (TKIs) are a class of chemotherapeutic drugs that are frequently implicated in new-onset cardiac pathologies among users. Cabozantinib (CBZ) is a TKI anticancer drug that has been associated with cardiotoxicity. Statins, a class of drugs widely known for their cardioprotective properties, are linked with both anticancer effects and cardioprotection during chemotherapy, but their effects are understudied when combined with TKIs. Purpose This study explores cardioprotective effects of statins when given with CBZ at a high-volume cancer center. Methods This is a retrospective cohort study of patients >18 given CBZ from 1/1/2010 to 11/30/2023 with ≥2 serial transthoracic echocardiograms (TTE). Key measures were baseline demographics, comorbidities, medications, TTE data, cancer therapeutics-related cardiac dysfunction (CTRCD), and major adverse cardiac events (MACE). CTRCD was defined as reduction in LVEF ≥10% to a value <53% from baseline on TTE, or symptomatic heart failure. MACE was defined as a new ICD-10 diagnosis or atrial fibrillation during therapy. Cohorts were statin (S) and non-statin (NS) patients. Primary endpoints were CTRCD within 2 years of CBZ exposure, MACE during exposure, and all-cause mortality. Hypothesis testing was conducted using Kruskal-Wallis, Chi-squared, and log-rank tests where relevant. Results We identified 77 CBZ-exposed patients with ≥2 serial TTEs, 44 of whom were on statins. Baseline demographics, cancer diagnosis, and anticancer therapy exposure were not significantly different between cohorts. There was no significant difference in CTRCD or MACE between cohorts. However, the S cohort had higher comorbidities of hyperlipidemia (p<0.001), hypertension (p=0.045), diabetes mellitus (p=0.003), coronary artery disease (p=0.005), and atrial fibrillation/flutter (p=0.013). Median survival times were 24.8 months in the S cohort (11 censored) and 14.8 months in the NS cohort (4 censored), p=0.139. Conclusion Increased comorbidities among statin users makes the association between CTRCD/MACE incidence and statin usage difficult to assess using the current sample size. However, despite the lack of demonstrable statistically significant difference between CTRCD/MACE incidence and statin usage, statin users had a greater median survival time of 10 months. This increased median survival time was evident even with 25% of the statin cohort censored, indicating potential life-prolonging effects when combined with TKIs. Studies in larger cohorts with adequate power are indicated to understand how statins may promote longevity in TKI-exposed patients.
No takes yet. Share an insight, caveat, or question.
Kline et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: